Institutional investors purchased a net $5.2 million shares of STML during the quarter ended March 2018. This may signal that the smart money is gaining interest in this company as the 68.72% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIDELITY MANAGEMENT & RESEARCH C... Bought 1.3 Million shares of Stemline Therapeutics Inc